Periodontal Therapeutic Market to Post 9.2% CAGR During 2018 to 2023
Market Overview:
Periodontal continues to
be one of the major causes of tooth loss and a major oral health issue. The
disease is common in both developed and developing countries, affecting nearly
20 to 50% of the global population. Over the years, different periodontal
therapies have come up with a high degree of effectivity. Both surgical and
non-surgical treatment options available.
Global Periodontal Therapeutic Market
is set to witness a strong growth in the forthcoming years. The latest study
conducted by Market Research Future (MRFR) reveals that the global periodontal
therapeutic market will surge at 9.2% CAGR during 2018 to 2023.
The onset of periodontal issues could be triggered
by poor oral hygiene, diabetes mellitus, stress, smoking and hormonal changes
in females. The incidence rate has continued to grow, which is also driving the
demand for periodontal therapeutic. As per World Health Organization (WHO), there
is a high incident rate of gingival bleeding in adults worldwide. Meanwhile, 10 to 15% of adults are affected with deep
periodontal pockets (6 mm or more) globally.
Competitive Landscape
·
Tolmar Inc
·
Align Technology Inc
·
3M-ESPE
·
Nobel Biocare Holdings AG
·
Orapharm
·
Valeant Pharmaceuticals
Int
·
Mallinckrodt
Pharmaceuticals
·
Teva Pharmaceutical
Industries Limited
·
Ultradent Products Inc
·
Eli Lilly & Company
·
Glidewell Laboratories
·
Den-Mat Holdings
Segmental Overview
·
The segmental analysis on
the global periodontal therapeutic market is based on treatment, type and end-users.
·
By treatment, the market
has bees segmented into local antibiotics and systematic antibiotics.
·
Based on type, the market
has been segmented into aggressive periodontitis, chronic periodontitis, gingivitis
and necrotizing periodontal disease.
·
By end-user, the market
has been segmented into hospitals and dental clinics
Global Periodontal
Therapeutic Market: Regional Segmentation
Key regions covered in MRFR’s report include Asia
Pacific, Europe, North America and the Middle East and Africa (MEA). In terms
of revenue, North America accounts for the predominant market share. This is
mainly owing to the higher prevalence of periodontal diseases among the elderly
population in countries such the U.S. and Canada. The data released by the Centers
for Disease Control and Prevention (CDC) reveals that nearly 50% of people in
the U.S. aged 30 of older suffer from periodontitis as advanced form of
periodontal disease. This is equivalent to around 64.7 Mn American with
periodontal diseases.
Europe is also viewed as an important market for
periodontal therapeutic. The prevalence rate in Europe has increased in recent
years. Factors such as an expanding elderly population, availability of
advanced healthcare services and effective reimbursement policies are playing
an important role in driving the market growth in Europe. The market in Europe
is expected to exhibit a steady growth during the forecast period.
Asia Pacific is the third largest market for
periodontal therapeutic and is expected to witness a strong growth over the
next couple of years. A large patient population coupled with increasing
healthcare expenditure will create significant opportunities for the market to
grow in APAC during the forecast period.
The MEA market holds significant potentials for
growth with GCC countries at the forefront of it. Rising standard of
healthcare, growing level of awareness and introduction of favourable policies
are factors propelling the market in MEA.
Comments
Post a Comment